Anocca announces authorisation pancreatic cancer trial

VIDAR-1 trial marks company’s clinical-stage debut

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition to a clinical-stage organisation.

The trial will evaluate advanced pancreatic cancer treatments and begins in Q2, 2025, at leading university hospitals in Sweden, Denmark, Germany and The Netherlands.

The VIDAR-1 programme, a phase 1/2 multi-product umbrella trial, focuses on patients with KRAS-positive advanced pancreatic cancer. Initially, it will investigate Anocca’s ANOC-001 therapy, which targets the KRAS G12V mutation. This therapy, a groundbreaking TCR-T cell solution, is the first non-viral gene-edited treatment approved for trials in Europe. ANOC-001 is manufactured at Anocca’s state-of-the-art cGMP facility.

Reagan Jarvis, co-founder and CEO, said: “This approval is a significant step in Anocca’s development as we transition to a clinical-stage company. ANOC-001 represents the first of many products that will advance to the clinic in the coming years.”

Phase 1 will initially enrol up to 20 patients per product, with additional countries and sites introduced in phase 2. The trial aims to address the unmet needs of pancreatic cancer patients, offering hope for improved outcomes through innovative treatments.

Zahid Bashir, Chief Medical Officer, addsed: “We are excited with the approval of VIDAR-1, as it represents a significant step towards addressing the unmet medical needs in patients with pancreatic cancer.”

The VIDAR-1 trial is designed to target oncogenic KRAS mutations within pancreatic ductal adenocarcinoma. Combining cutting-edge therapies with scalable production processes, Anocca seeks to deliver next-generation T-cell solutions that redefine cancer care.

By integrating innovative science and robust clinical methods, Anocca aims to provide new possibilities for patients and their care teams.